Core Scientific, Inc. (CORZ) financials: revenue, earnings and cash flow
Fiscal 2020–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Core Scientific’s revenue went from $60M in fiscal 2020 to $319M in fiscal 2025, growth of about 39.5% a year.
Net income in fiscal 2025 was -$289M, a net margin of -90.5%; the best year in this period was 2021 with $47M.
Over the twelve months to September 30, 2026, revenue was $592M and net income -$111M.
Free cash flow was -$451M in fiscal 2025 and positive in 1 of the 6 years shown.
The diluted share count rose 102% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $592M | $319M | $511M | $502M | $640M | $544M | $60M |
| Gross profit | $244M | $38M | $121M | $123M | $8M | $239M | $9M |
| Operating income | -$434M | -$246M | -$142M | $9M | -$2.1B | $131M | -$6M |
| Net income | -$111M | -$289M | -$1.4B | -$246M | -$2.1B | $47M | -$12M |
| EPS (diluted) | $-0.33 | $-0.88 | $-4.87 | $-0.65 | $-6.30 | $0.20 | $-0.14 |
| R&D | — | — | $12M | $7M | $27M | $8M | $5M |
| Revenue growth | — | −37.5% | +1.7% | −21.5% | +17.6% | +802.7% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $454M | $278M | $43M | $65M | $205M | -$57M | -$24M |
| Capital spending | -$1.8B | -$729M | -$95M | -$16M | -$384M | $0 | $0 |
| Free cash flow | -$1.3B | -$451M | -$52M | $49M | -$179M | -$57M | -$24M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | $0 | $0 | $32M | — | — |
| Stock-based pay | $89M | $98M | $52M | $59M | $183M | $39M | $3M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash | — | $311M | $836M | $50M | $16M | $118M | $9M |
| Debt | — | $1.2B | $1.2B | $810M | $38M | $730M | — |
| Equity | — | -$963M | -$943M | -$597M | -$409M | $1.3B | $0 |
| Total assets | — | $2.3B | $1.5B | $712M | $808M | $2.4B | $15000 |
| Shares (diluted) | 324M | 318M | 256M | 380M | 341M | 233M | 158M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Gross margin | 41.2% | 11.9% | 23.7% | 24.6% | 1.3% | 43.9% | 15.6% |
| Operating margin | -73.3% | -77.0% | -27.8% | 1.8% | -329.5% | 24.1% | -10.5% |
| Net margin | -18.8% | -90.5% | -281.6% | -49.1% | -335.2% | 8.7% | -20.2% |
| FCF margin | -223.0% | -141.3% | -10.2% | 9.7% | -27.9% | -10.4% | -39.4% |
| ROIC | — | -97.5% | -44.0% | 3.3% | — | 4.8% | — |
| ROE | — | 30.0% | 152.5% | 41.3% | 524.3% | 3.5% | — |
Frequently asked questions
What is Core Scientific’s annual revenue?
$319M in fiscal 2025 and $592M over the twelve months to September 30, 2026.
How much profit does Core Scientific make?
Net income was -$289M in fiscal 2025 (net margin -90.5%).
Is Core Scientific’s revenue growing?
No: revenue fell 37.5% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.